Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QURE 
Uniqure NV (QURE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: QURE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
13 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $37.58
1 Year Target Price $37.58
| 9 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.78% | Avg. Invested days 21 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 793.92M USD | Price to earnings Ratio - | 1Y Target Price 37.58 |
Price to earnings Ratio - | 1Y Target Price 37.58 | ||
Volume (30-day avg) 13 | Beta 0.13 | 52 Weeks Range 4.45 - 19.18 | Updated Date 09/16/2025 |
52 Weeks Range 4.45 - 19.18 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.9 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -790.78% |
Management Effectiveness
Return on Assets (TTM) -15.39% | Return on Equity (TTM) -427.47% |
Valuation
Trailing PE - | Forward PE 27.93 | Enterprise Value 483647477 | Price to Sales(TTM) 55.38 |
Enterprise Value 483647477 | Price to Sales(TTM) 55.38 | ||
Enterprise Value to Revenue 35.13 | Enterprise Value to EBITDA 0.99 | Shares Outstanding 54866900 | Shares Floating 38737699 |
Shares Outstanding 54866900 | Shares Floating 38737699 | ||
Percent Insiders 6.08 | Percent Institutions 96.92 |
Upturn AI SWOT
Uniqure NV
Company Overview
History and Background
UniQure N.V. was founded in 1998 and is headquartered in Amsterdam, Netherlands. It is a pioneer in gene therapy, focusing on developing and commercializing innovative therapies for patients with severe genetic diseases. The company has evolved from early research stages to having a commercially available product, Glybera (later divested), and a pipeline of gene therapy candidates.
Core Business Areas
- Gene Therapy Development: UniQure focuses on developing and commercializing gene therapies targeting severe genetic diseases. Their core expertise lies in adeno-associated virus (AAV) based gene therapies.
- Manufacturing: UniQure has developed manufacturing capabilities for producing AAV vectors, crucial for their gene therapy products.
- Research and Development: Ongoing research and development efforts are dedicated to expanding their pipeline with new gene therapy candidates and improving existing technologies.
Leadership and Structure
The leadership team is comprised of experienced executives in biotechnology and pharmaceuticals. The organizational structure includes departments for research and development, clinical trials, manufacturing, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- Hemgenix (etranacogene dezaparvovec): Hemgenix is a gene therapy for adults with hemophilia B. Approved by the FDA in November 2022, it aims to provide long-term factor IX expression and reduce the need for regular infusions. Competitors include other factor IX replacement therapies and emerging gene therapies from companies like CSL Behring.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly growing, driven by advancements in vector technology and a growing understanding of disease genetics. It is characterized by high development costs, complex regulatory pathways, and significant potential for treating previously incurable diseases.
Positioning
UniQure is positioned as a pioneer in gene therapy, with expertise in AAV vector technology and a focus on developing therapies for severe genetic diseases. Their competitive advantage lies in their established manufacturing capabilities and clinical experience. They are one of the first companies to successfully bring a gene therapy to market.
Total Addressable Market (TAM)
The TAM for gene therapies is estimated to be in the tens of billions of dollars, growing rapidly as more therapies are approved and adopted. UniQure is positioned to capture a significant share of this market, particularly in areas like hemophilia B.
Upturn SWOT Analysis
Strengths
- Pioneering gene therapy experience
- Established AAV vector technology
- FDA-approved gene therapy (Hemgenix)
- Proprietary manufacturing capabilities
- Strong intellectual property portfolio
Weaknesses
- High development costs
- Regulatory hurdles
- Limited commercial infrastructure
- Dependence on AAV vector technology
- Relatively small market capitalization compared to larger competitors
Opportunities
- Expanding pipeline with new gene therapy candidates
- Partnerships with larger pharmaceutical companies
- Growing market for gene therapies
- Advancements in vector technology
- Expanding geographic reach
Threats
- Competition from other gene therapy companies
- Regulatory challenges
- Manufacturing issues
- Clinical trial failures
- Pricing and reimbursement pressures
Competitors and Market Share
Key Competitors
- CSL Behring (CSLLY)
- Biogen (BIIB)
- Sangamo Therapeutics (SGMO)
Competitive Landscape
UniQure's advantages include its AAV expertise and Hemgenix. Disadvantages include competition from larger pharmaceutical companies with greater resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the development and commercialization of Hemgenix and progress in the pipeline.
Future Projections: Future growth projections will depend on the success of Hemgenix and the pipeline.
Recent Initiatives: Recent strategic initiatives include the commercial launch of Hemgenix and continued investment in research and development.
Summary
UniQure is a pioneering gene therapy company with an FDA-approved product, Hemgenix, for hemophilia B. The company's strengths lie in its AAV vector technology and manufacturing capabilities. However, UniQure faces challenges related to high development costs, regulatory hurdles, and competition from larger pharmaceutical companies. The success of Hemgenix and the development of its pipeline will be crucial for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company reports
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Actual results may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Uniqure NV
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2007-06-20 | CEO & Executive Director Mr. Matthew Craig Kapusta CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 209 | Website https://www.uniqure.com |
Full time employees 209 | Website https://www.uniqure.com | ||
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.